Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay
Nonsense-mediated mRNA decay (NMD) degrades transcripts with premature stop codons. Given the prevalence of nonsense single nucleotide polymorphisms (SNPs) in the general population, it is urgent to catalog the effects of clinically approved drugs on NMD activity: any interference could alter the ex...
Saved in:
Main Authors: | Jingrong Zhao (Author), Zhelin Li (Author), Ruchira Puri (Author), Kelvin Liu (Author), Israel Nunez (Author), Liang Chen (Author), Sika Zheng (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing the activity of nonsense-mediated mRNA decay in lung cancer
by: Meng Wang, et al.
Published: (2017) -
FDA approval of Pfizer-BioNTech: Evaluating the significance of mRNA vaccine approval
by: Syed Abdullah Monawwer, et al.
Published: (2021) -
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression
by: Daniel Meraviglia-Crivelli, et al.
Published: (2022) -
Long noncoding RNA SMUL suppresses SMURF2 production-mediated muscle atrophy via nonsense-mediated mRNA decay
by: Bolin Cai, et al.
Published: (2021) -
Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons
by: Nesrine Benslimane, et al.
Published: (2024)